- Archivo PDF del volumen: Download full issue
- Archivo PDF del volumen: Download full issue
- Archivo PDF del volumen: Download full issue
- Archivo PDF del volumen: Download full issue
Previous issues
Editorials
Translational research in the new era of percutaneous mitral valve interventions
REC Interv Cardiol. 2021;3:1-2
Elderly patients with comorbidities and acute coronary syndrome: ¿primum non nocere?
REC Interv Cardiol. 2021;3:3-4
Virtual vs face-to-face meetings. Can both of them coexist?
REC Interv Cardiol. 2021;3:5-7
Original Articles
Experimental model of mitral regurgitation in a porcine model
REC Interv Cardiol. 2021;3:8-14
Impact of comorbidities in the decision of using invasive management in elderly patients with NSTEACS
REC Interv Cardiol. 2021;3:15-20
Microalbuminuria predicts contrast-induced nephropathy in patients with acute coronary syndrome
REC Interv Cardiol. 2021;3:21-25
Use of subcutaneous nitroglycerin to facilitate transradial access in coronary procedures (NiSAR Study)
REC Interv Cardiol. 2021;3:26-32
Special article
Update on requirements and equipment in interventional cardiology. Consensus document by the Interventional Cardiology Association and the Ischemic Heart Disease and Acute Cardiac Care Association of the Spanish Society of Cardiology and the Spanish Association of Nursing in Cardiology
REC Interv Cardiol. 2021;3:33-44
Review Article
Left main coronary artery percutaneous revascularization: alea jacta est
REC Interv Cardiol. 2021;3:45-54
Debate
Debate: Refractory angina. The Reducer device as a new therapeutic approach. Perspective from the clinic
REC Interv Cardiol. 2021;3:59-61
Debate: Refractory angina. The Reducer device as a new therapeurefractic approach. Perspective from interventional cardiology
REC Interv Cardiol. 2021;3:62-64
Clinical Case
Percutaneous management of recurrent prosthetic valve thrombosis
REC Interv Cardiol. 2021;3:73-74
Percutaneous management of recurrent prosthetic valve thrombosis. How would I approach it?
REC Interv Cardiol. 2021;3:74-75
Percutaneous management of recurrent prosthetic valve thrombosis. Case resolution
REC Interv Cardiol. 2021;3:75-77
Review Article
Cerebral embolic protection device in TAVI after the REFLECT II clinical trial: does it change our strategy?
REC Interv Cardiol. 2021;3:55-58
Images in cardiology
Left main coronary artery perforation after rotational atherectomy
REC Interv Cardiol. 2021;3:78-79
Deployment of cerebral protection device in complex anatomy
REC Interv Cardiol. 2021;3:80-81
Magmaris bioresorbable stent: cardiac CT follow-up
REC Interv Cardiol. 2021;3:82
Scientific letters
Cardiovascular interventions live: show or training? The professional perspective: the LIVE study
REC Interv Cardiol. 2021;3:65-66
Anomalous origin of left circumflex artery from the right pulmonary artery of an adult
REC Interv Cardiol. 2021;3:67-69
Transcatheter aortic valve migration in aortic regurgitation following left ventricular assist device
REC Interv Cardiol. 2021;3:69-71
Effects of the COVID-19 pandemic on the population over 75 years old with coronary artery disease. The EPIC SIERRA 75 registry
REC Interv Cardiol. 2021;3:71-72
Congresses abstracts
Editor's page
Original articles
Editorials
Original articles
Editorials
Drug-coated balloon for the treatment of bifurcation lesions: high enthusiasm, but still limited evidence
aServicio de Cardiología, Hospital Reina Sofía, Universidad de Córdoba (IMIBIC), Cordoba, Spain
bCentro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain
Original articles
Review Articles
Interviews
An interview with Augusto D. Pichard
aServicio de Cardiología, Hospital Universitario de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain
bGrupo de Investigación en Enfermedades Cardiovasculares (BIO-HEART), Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), L’Hospitalet de Llobregat, Barcelona, Spain
Scientific letters
Images in cardiology
Original articles
Letters to the Editor
Beyond “leave nothing behind”: reconsidering biological restoration after drug-coated balloon coronary intervention. Response
aDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele-Milan, Milan, Italy
bDivision of Cardiology, IRCCS Humanitas Research Hospital, Rozzano-Milan, Milan, Italy
cDivision of Cardiology, Montefiore Medical Center, Bronx, New York, United States
dDivision of Cardiology, White Plains Hospital, White Plains, New York, United States

